AKR1C3 and rectal cancer: Drugs traditionally used in the adjuvant treatment of rectal cancer were reported in the network dependencies: capecitabine, 5-fluorouracil (both targeting AKR1C3), irinotecan and oxaliplatin (Figure 3 panel b) and (Supplemental table 4).